OKYO News and Press, OKYO Pharma Limited From 01/05/24

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...

LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...

2023-10-31 13:18:43 ET More on OKYO Pharma OKYO shares retreat 12% after rallying ahead of Phase 2 study update OKYO Pharma announces capital raise of $3.95M without any underwriter or agent Financial information for OKYO Pharma For further details see: O...

Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, m...

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...

2023-10-06 08:53:38 ET OMNIQ ( OMQS ) -44% announces pricing of public offering. Wheeler Real Estate Investment Trust  ( WHLR ) -21% . ShiftPixy  ( PIXY ) -19% . Nanobiotix  ( NBTX ) -15% . Aehr Test ( AEHR ) -11% . ...

2023-10-05 11:53:30 ET More on OKYO Pharma OKYO Pharma announces capital raise of $3.95M without any underwriter or agent OKYO Pharma rebounds on withdrawal of equity offering Financial information for OKYO Pharma For further details see: OKYO shares retr...

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. The dropout rate is 5.4% and unrelated to side effects. Top-...

2023-09-15 08:14:04 ET More on pre-market losers stock: Compare metrics for AXLA to HNST, SLE Honest Company: Honestly Bad Economics The Honest Company: Very Few Options The Honest Company, Inc. ( HNST ) Q2 2023 Earnings Call Transcript The Honest...

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...